

Acorn Cardiovascular

[View the current Acorn Cardiovascular Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32517-Acorn+Cardiovascular.html)

(<http://www.bioportfolio.com/biocorporate/32517-Acorn+Cardiovascular.html>)

Contact Details:

601 Campus Drive

St. Paul,

Minnesota

55112

United States of America

Tel: 651-286-4800

Fax: 651-286-4848

Email: info@acorncv.com

Acorn Cardiovascular™ is a privately held medical device company that was incorporated in 1996 and is located in St. Paul, Minnesota, USA. Mission: Acorn Cardiovascular develops innovative solutions to successfully treat patients with heart failure and restore hope for a better, longer life. Background: Heart failure (HF) is a condition that is caused by damage to the heart muscle, which results in the inability of the heart to pump enough blood to meet the needs of the body. This highly debilitating and progressive disorder affects more than five million people in the United States and 25 million people worldwide. An estimated 550,000 new HF cases are diagnosed each year in the United States alone. Heart failure can be caused by or is the end result of a number of conditions, including coronary artery disease, prolonged high blood pressure, poor valve function or other cardiovascular abnormalities. CorCap™ Cardiac Support Device (CSD): The company's introductory product, the CorCap™ Cardiac Support Device (CSD), is proprietary mesh wrap that is placed around the heart to provide gentle, permanent support. It is intended to prevent and reverse the progression of heart failure by improving the heart's structure and function, leading to improvements in the quality of a patient's life. The CorCap CSD received CE marking in September 2000. Randomized clinical trials evaluating effectiveness of the CorCap CSD have been completed in North America and Europe. The CorCap CSD has been used in the treatment of more than 460 patients worldwide.

Recent Publications by Acorn Cardiovascular:



- [Design and features of the Acorn CorCap Cardiac Support Device: the concept of passive mechanical diastolic support.](#)

The Laplace equation points to the importance of ventricular wall stress... 17th March, 2006
Acorn Cardiovascular, Inc., 651 Campus Drive, St. Paul, MN 55112, USA.- Heart Fail Rev. 2005 Jun;10(2):101-7. ([DOI Direct Link](#))

- [Development and validation of a patient questionnaire to determine New York Heart Association](#)

[classification.](#)

*BACKGROUND: New York Heart Association (NYHA) classification correlates...17th December, 2004
Acorn Cardiovascular Inc., St. Paul, Minnesota 55112, USA.- J Card Fail. 2004 Jun;10(3):228-35.*

Press Releases on Acorn Cardiovascular:

Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism	6th November, 2009	Wolters Kluwer Health: Lippincott Williams & Wilkins	<i>-- Venous Thromboembolism: What Is Preventing Achievement of Performance Measures and Consensus Guidelines? by Jane Nelson Worel, MS, APRN-BC, APNP "Nurses in acute care FRAMINGHAM, Mass. and SYDNEY, Nov. 6 /PRNewswire-FirstCall/ --</i>
HeartWare to Present at Upcoming Investment Conferences in November	6th November, 2009	HeartWare International, Inc.	<i>HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) a leading innovator and provider of less invasive, miniaturized circulatory</i>
Volcano Reports 22 Percent Increase in Third Quarter Revenues	5th November, 2009	Volcano Corporation	<i>SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and</i>
Reportlinker Adds Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads	5th November, 2009	Reportlinker	<i>NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads</i>
WorldHeart to Present at Canaccord Adams Cardiovascular Conference	5th November, 2009	WorldHeart Corporation	<i>SALT LAKE CITY, Nov. 5 /PRNewswire-FirstCall/ -- WorldHeart Corporation (Nasdaq: WHRT) today announced that J. Alex Martin, President and Chief Executive Officer, is scheduled to make an investor</i>

Acorn Cardiovascular Clinical Trials:



- [Confirmation Trial of the Acorn CorCap Cardiac Support Device \(CSD\) at the Same Time as Mitral Valve Repair](#)

Acorn Cardiovascular Patents:



- 6174279- [Cardiac constraint with tension indicator](#)
- 6572533- [Cardiac disease treatment and device](#)
- 6575921- [Device for heart measurement](#)
- 6579226- [Delivery of cardiac constraint jacket](#)
- 6582355- [Cardiac disease treatment method](#)
- 6587734- [Cardio therapeutic heart sack](#)
- 6645139- [Bag for at least partially enveloping a heart](#)
- 6673009- [Adjustment clamp](#)
- 6682475- [Tension indicator for cardiac support device and method therefore](#)
- 6682476- [Cardiac disease treatment and device](#)
- 6689048- [Delivery of cardiac constraint jacket](#)
- 6567699- [Defibrillating cardiac constraint](#)
- 6564094- [Cardiac disease treatment and device](#)
- 6544168- [Cardiac reinforcement device](#)
- 6179791- [Device for heart measurement](#)
- 6193648- [Cardiac constraint with draw string tensioning](#)
- 6230714- [Cardiac constraint with prior venus occlusion methods](#)
- 6293906- [Delivery of cardiac constraint jacket](#)
- 6370429- [Defibrillating cardiac constraint](#)
- 6375608- [Cardiac reinforcement device](#)
- 6416459- [Bag for at least partially enveloping a heart](#)
- 6425856- [Cardiac disease treatment and device](#)
- 6482146- [Cardiac disease treatment and device](#)
- 6537203- [Cardiac disease treatment and device](#)
- 6730016- [Cardiac disease treatment and device](#)
- 6755779- [Apparatus and method for delivery of cardiac constraint jacket](#)
- 7166071- [Cardiac reinforcement device](#)
- 7214181- [Septum attached ventricular support](#)
- 7235042- [Apparatus and method for applying cardiac support device](#)
- 7252632- [Cardiac disease treatment and device](#)
- 7255674- [Cardiac reinforcement device](#)
- 7261684- [Cardiac reinforcement device](#)

- 7278964- [Cardiac reinforcement device](#)
- 7326174- [Cardiac disease treatment and device](#)
- 7351200- [Cardiac reinforcement device](#)
- 7419466- [Delivery of cardiac constraint jacket](#)
- 7163507- [Cardiac reinforcement device](#)
- 7153258- [Cardiac support disease with anti-fibrosis coating](#)
- 7025719- [Metallic cardiac support device](#)
- 6876887- [Cardio therapeutic heart sack](#)
- 6881185- [Delivery of cardiac constraint jacket](#)
- 6893392- [Cardiac reinforcement device](#)
- 6896652- [Cardiac disease treatment and device](#)
- 6902522- [Cardiac disease treatment and device](#)
- 6902524- [Cardiac disease treatment and device](#)
- 6908426- [Cardiac disease treatment and device](#)
- 6951534- [Cardiac support device](#)
- 6997865- [Cardiac support device with anti-fibrosis lining](#)
- 7022064- [Cardiac support with controlled ventricular pressure](#)
- 7575547- [Cardiac support device with anti-fibrosis coating](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

